Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies

Sulfonylureas are widely prescribed all over the world, mainly because of their high effectiveness. At the same time, the heterogeneity of the group is obvious, primarily in relation to the effect of drugs on the risk of developing hypoglycemic events. The review presents the results of new studies,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	I. V. Kononenko, O. M. Smirnova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2021
Materias:	type 2 diabetes mellitus modified release gliclazide efficacy safety hypoglycemic events ramadan Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/1cedd6659ae54643b631cefee6a10323
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1cedd6659ae54643b631cefee6a10323
record_format	dspace
spelling	oai:doaj.org-article:1cedd6659ae54643b631cefee6a103232021-11-14T09:00:23ZLow risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies2072-03512072-037810.14341/DM12768https://doaj.org/article/1cedd6659ae54643b631cefee6a103232021-11-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12768https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Sulfonylureas are widely prescribed all over the world, mainly because of their high effectiveness. At the same time, the heterogeneity of the group is obvious, primarily in relation to the effect of drugs on the risk of developing hypoglycemic events. The review presents the results of new studies, including «Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes» and results of a model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes, confirming the higher efficacy of modified release gliclazide (gliclazide MB) compared to DPP-4, as well as a low risk of hypoglycemic conditions. The results of recent studies, as well as the results of the ADVANCE and ADVANCE-ON studies, suggest that gliclazide MB is safe to use as a second-line drug, especially in patients with chronic kidney disease.I. V. KononenkoO. M. SmirnovaEndocrinology Research Centrearticletype 2 diabetes mellitusmodified release gliclazideefficacysafetyhypoglycemic eventsramadanNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 24, Iss 4, Pp 350-356 (2021)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus modified release gliclazide efficacy safety hypoglycemic events ramadan Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus modified release gliclazide efficacy safety hypoglycemic events ramadan Nutritional diseases. Deficiency diseases RC620-627 I. V. Kononenko O. M. Smirnova Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies
description	Sulfonylureas are widely prescribed all over the world, mainly because of their high effectiveness. At the same time, the heterogeneity of the group is obvious, primarily in relation to the effect of drugs on the risk of developing hypoglycemic events. The review presents the results of new studies, including «Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes» and results of a model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes, confirming the higher efficacy of modified release gliclazide (gliclazide MB) compared to DPP-4, as well as a low risk of hypoglycemic conditions. The results of recent studies, as well as the results of the ADVANCE and ADVANCE-ON studies, suggest that gliclazide MB is safe to use as a second-line drug, especially in patients with chronic kidney disease.
format	article
author	I. V. Kononenko O. M. Smirnova
author_facet	I. V. Kononenko O. M. Smirnova
author_sort	I. V. Kononenko
title	Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies
title_short	Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies
title_full	Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies
title_fullStr	Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies
title_full_unstemmed	Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies
title_sort	low risk of hypoglycemia and high efficacy of gliclazide mb: results of recent studies
publisher	Endocrinology Research Centre
publishDate	2021
url	https://doaj.org/article/1cedd6659ae54643b631cefee6a10323
work_keys_str_mv	AT ivkononenko lowriskofhypoglycemiaandhighefficacyofgliclazidembresultsofrecentstudies AT omsmirnova lowriskofhypoglycemiaandhighefficacyofgliclazidembresultsofrecentstudies
_version_	1718429453122535424

Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies

Ejemplares similares